Gram-negative bacterial surface antigens (Escherichia coli and Klebsiella pneumoniae)

Gram-negative bacterial surface antigens on Escherichia coli and Klebsiella pneumoniae represent a complex group of molecules located on the outer membrane of these pathogens, including lipopolysaccharides (LPS), outer membrane proteins (OMPs), and capsular polysaccharides (CPS). These antigens are essential for bacterial survival, providing structural stability and acting as a barrier against environmental stressors and antibiotics. In clinical settings, these surface components are primary targets for the host immune system and are recognized as major virulence factors that drive the pathogenesis of infections such as sepsis, pneumonia, and urinary tract infections. LPS, in particular, is a potent inducer of the inflammatory cascade, while the capsule (CPS) allows bacteria to evade phagocytosis. Therapeutic interventions targeting these antigens include polymyxin antibiotics, which disrupt the LPS layer, and various vaccines and monoclonal antibodies currently in development that aim to neutralize specific serotypes. However, the high diversity of these antigens among different strains and the risk of endotoxin release during treatment present significant challenges for drug development and patient safety.

Other names

LipopolysaccharideLPSEndotoxinOuter membrane proteinsOMPsCapsular polysaccharidesCPSO-antigenK-antigenBacterial cell wall antigens

Drugs targeting these antigens primarily work through: 1) Binding to the lipid A portion of lipopolysaccharide (LPS) to disrupt the outer membrane (e.g., Polymyxins); 2) Opsonization and neutralization of surface antigens to facilitate phagocytosis and prevent immune evasion (e.g., vaccines and monoclonal antibodies); 3) Utilizing surface transport proteins to bypass the outer membrane barrier (e.g., Cefiderocol).